Table 1.
Cohort description (n = 176)
| patient number (%) | ||
|---|---|---|
| Age at diagnosis (y) | Mean (median) | 59.2y (61 y) |
| Histological Type | Serous-papillary | 148 (84.0) |
| Endometrioid | 10 (5.7) | |
| Mucinous | 4 (2.3) | |
| Others/unknown | 14 (8.0) | |
| FIGO stage | FIGO IA-IC | 8 (4.6) |
| FIGO IIA-IIB | 6 (3.4) | |
| FIGO IIIA-IIIC | 125 (71.0) | |
| FIGO IV | 37 (21.0) | |
| Nodal involvement | Negative | 44 (25.0) |
| Positive | 101 (57.4) | |
| Unknown | 31 (17.6) | |
| Grading | G1 | 9 (5.1) |
| G2 | 46 (26.1) | |
| G3 | 117 (66.5) | |
| Unknown | 4 (2.3) | |
| Distant metastasis | Negative | 138 (78.4) |
| Positive | 37 (21.0) | |
| Unknown | 1 (0.6) | |
| Tumour residuum after surgery | Not macroscopically visible | 122 (69.3) |
| <1 cm3 | 33 (18.8) | |
| >1 cm3 | 19 (10.8) | |
| Unknown | 2 (1.1) | |
| Adj. Chemotherapy | Carboplatin/Paclitaxel (Taxol) | 127 (72.2) |
| Other regimens based on carboplatin | 35 (19.9) | |
| Others | 14 (7.9) | |
| Recurrence | Yes | 114 (64.8) |
| No | 57 (32.4) | |
| Unknown | 5 (2.8) | |
| Survival at last follow-up | Alive | 83 (47.2) |
| Dead | 93 (52.8) | |
| Recurrence-free survival (months) | Mean (median) | 27.4 (16) |
| Overall survival (months) | Mean (median) | 38.4 (30.5) |